ZYBERNO
Stock Report
Updated Aug 30, 2026

Structure Therapeutics Inc. (GPCR)

Healthcare • NASDAQ

$47.37

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
18.0/100
POOR BUSINESS
Structure Therapeutics Inc. (GPCR) scores 18/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-25.4%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.01x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-1,608.4%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Structure Therapeutics Inc. (GPCR) stock report — Zyberno Score 18/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, GPCR generated -$156.31M in Owner Earnings. Capital was deployed as follows: $4.48M invested in capital expenditures. Reinvestment rate: -0.8%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:47.37
Market Cap:$10.32B

Valuation Multiples (2)

P/B Ratio:7.62x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$8.99B

Price Action & Momentum (1)

% of 52-Week High:49.9%
B. Profitability Assessment

Return Metrics (5)

ROA:-24.2%
Reinvestment Rate:-0.8%
Fundamental Growth Rate (g):12.7%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$3.46
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:20.75x
Quick Ratio:20.75x
Cash Ratio:20.31x

Leverage Analysis (3)

Debt To Equity Ttm:0.01x
Debt-to-Equity Ratio:0.01x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:1,305,915,000.00
Cash And Cash Equivalents:1,342,700,000.00
Long Term Debt:$3.63M
Net Debt:-$1.34B
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$384.57M

Bottom Line Performance (3)

-$323.33M
Income Before Tax:-$322.39M
Ebitda Ttm:-382,934,000.00

Operating Expenses (5)

Operating Expenses:384,569,000.00
R And D Expense:294,242,000.00
Sga Expense:73,814,000.00
Income Tax Expense:$702.00K
Interest Expense:0.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$1.43B
Current Assets:$1.37B
Ppe Net:6,332,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:71,011,000.00
Current Liabilities:66,113,000.00
Long Term Debt:$3.63M
Short Term Debt:$2.60M

Equity & Capital (3)

Equity:$1.35B
Retained Earnings:-$652.43M
Common Stock:500,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:11,131,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:12,634,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$154.74M-$159.22M

Investment Activities (2)

Investing Cash Flow:-$496.95M
Capital Expenditures Ttm:4,482,000.00

Financing Activities (3)

Financing Cash Flow:-$1.74M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:514,573,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:1,635,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-1.64
-$1.64
Earnings Per Share Ttm:-$1.48

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$1.02

Book Value & Capital (2)

Book Value Per Share:$6.21
Cash Per Share:6.16

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$156.31M

Damodaran Growth Analysis (2)

Reinvestment Rate:-0.8%
Fundamental Growth Rate (g):12.7%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):85.0%
C. Company Profile & Context

Corporate Information (6)

Symbol:GPCR
Company Name:Structure Therapeutics Inc.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:medium
Volume Category:N/A

Share Structure (3)

Shares Outstanding:217.96M
Shares Outstanding Basic:217.96M
Shares Outstanding Diluted:217.96M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-30 21:33:49 UTC
Data Timestamp:2026-08-30T21:33:49.258924
Scroll to Top